What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “KT502 is a monoclonal antibody that depletes B cells by targeting CD19 and CD3”In the company’s words, NCT07564154 on ClinicalTrials.gov
- Tested for
- Rheumatoid Arthritis (RA)
- Main trialPhase 1
- “This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT502 administered subcutaneously to participants with Rheumatoid Arthritis (RA). The study will have 2 parts: Part A is a single ascending dose finding (SAD) and Part B is dose escalation by fractionated dosing.”In the company’s words, NCT07564154 on ClinicalTrials.gov
Other drugs for Rheumatoid Arthritis (RA)
- TLL-018Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- UpadacitinibAbbVie · Phase 3
- AbataceptBristol Myers Squibb · Phase 3
- AdalimumabAbbVie · Phase 3
- AnakinraSwedish Orphan Biovitrum · Phase 3
Coming up1
- Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Dec 2027 | A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026